INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH (ISPOR) EXPANDS LEADERSHIP TEAM

Published Oct 28, 2015

BETSY LANE JOINS ISPOR AS CHIEF MARKETING & COMMUNICATIONS OFFICER 

Princeton, NJ—October 28, 2015—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced that Betsy Lane has been appointed director and chief marketing and communications officer for the organization. Lane will lead ISPOR’s global marketing and communications efforts to help further advance the organization’s mission to promote health economics and outcomes research excellence to improve decision making for health globally. Lane has over 25 years’ experience in the life sciences industry. Prior to joining ISPOR, she served as senior vice president, marketing and communications at Publicis Touchpoint Solutions. Previously, she worked for several medical advertising agencies leading agency teams primarily focused on specialty product launches in the oncology, endocrinology, CNS, and dermatology therapeutic areas. Lane began her career working as a pharmaceutical sales representative. While at Johnson & Johnson, she served in a variety of increasingly significant roles, including divisional sales manager and product manager. “We are excited to have Betsy join the ISPOR team,” stated Nancy Berg, chief executive officer and executive director. “Our organization has grown tremendously over the years and we believe that Betsy’s experience will help us to further our mission by more effectively communicating the great work that ISPOR does day in and day out.”

###

Related Stories

New Research Collection Reveals How Artificial Intelligence Is Reshaping Health Economics

Nov 6, 2025

The PhRMA Foundation and ISPOR announced the publication of a special themed section of research papers that explores the dynamic intersection of artificial intelligence (AI) and health economics and outcomes research (HEOR).

ISPOR Announces 2025 Health Economics and Outcomes Research Award Honorees

Oct 20, 2025

ISPOR announced the recipients of its 2025 Health Economics and Outcomes Research (HEOR) Scientific and Leadership Awards. ISPOR Scientific Awards are designed to foster and recognize excellence and outstanding achievement in HEOR and its Leadership Awards recognize excellence and outstanding leadership in the field.

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×